mavorixafor will enhance the level or influence of triazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe. Keep track of for adverse results of delicate CYP3A4 substrates if coadministered with mavorixafor (a weak CYP3A4 inhibitor).
The estimated history risk of significant birth defects and miscarriage for the indicated inhabitants is not known. All pregnancies Have a very track record threat of birth defect, decline, or other adverse outcomes.
Contraindicated (1)nirmatrelvir will increase the level or outcome of triazolam by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
Exceptions to this monograph are talked over in even more depth in individual drug interaction monographs. Look at therapy modification
Voxelotor increases systemic exposure of delicate CYP3A4 substrates. Prevent coadministration with sensitive CYP3A4 substrates having a narrow therapeutic index. Consider dose reduction with the delicate CYP3A4 substrate(s) if unable to steer clear of.
phenobarbital will lessen the level or result of triazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
budesonide will minimize the extent or outcome of triazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
These agents ought to only be mixed if substitute procedure solutions are insufficient. If blended, limit the dosages and period of every drug. Contemplate therapy modification
Bodily dependence and withdrawal reactions. Estazolam might cause Actual physical dependence and withdrawal reactions, particularly when you continue to take estazolam for quite a few days to quite a few months.
lapatinib will improve the amount or outcome of triazolam by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
Contraindicated (2)itraconazole will enhance the degree or outcome of triazolam by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Both of those medicine will improve QT interval
prednisone will lessen the extent or influence of triazolam by influencing hepatic/intestinal Eszopiclone enzyme CYP3A4 metabolism. Use Caution/Keep track of.
zafirlukast will increase the level or outcome of triazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
These agents ought to only be mixed if different therapy alternatives are inadequate. If blended, limit the dosages and length of each drug. Contemplate therapy modification